Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
MammaPrint has successfully reached level 3 in evidence-based medicine
January 13th, 2005
Agendia, a genomics company based in Amsterdam the Netherlands, working in close collaboration with the Transbig translational research network, announced at the San Antonio Breast Cancer conference that the 70-gene expression signature (MammaPrint) outperformed all currently-used standard diagnostic criteria in predicting future development of distant metastases and overall survival in a large breast cancer study. The international validation project was led by Transbig. The data analysis was carried out independently by a statistical team in Belgium. The Transbig consortium intends to use the MammaPrint test in MINDACT, a large, prospective,...
Source: Women's Health Weekly (2005-01-13)
|
